Myriad Genetics Newswire

Myriad Genetics Newswire

Comprehensive Real-Time News Feed for Myriad Genetics.

Results 1 - 20 of 438 in Myriad Genetics

  1. Analysts Set Myriad Genetics, Inc. (NASDAQ:MYGN) Target Price at $42.58Read the original story w/Photo

    1 hr ago | Daily Political

    Shares of Myriad Genetics, Inc. have received a consensus recommendation of "Hold" from the seventeen analysts that are presently covering the company. Two analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and nine have assigned a buy recommendation to the company.

    Comment?

  2. The Recent PTO Guidance on Subject Matter Eligibility: LessonsRead the original story w/Photo

    Thursday | JD Supra

    ... to the Supreme Court's decisions in Mayo v. Prometheus Labs and Association of Molecular Pathologists v. Myriad Genetics ( see " USPTO Provides Update on Myriad-Mayo Guidance "). General Linck voiced her disappointment at the manner in which the ...

    Comment?

  3. ACLU skirmishes with local genetic testing companyRead the original story w/Photo

    Wednesday | Deseret News

    The American Civil Liberties Union is pressing ahead with a complaint against a Salt Lake City-based molecular diagnostics company on behalf of four patients who say they were refused access to their complete testing results. Sandra Park, a lawyer with the ACLU, said the organization filed the complaint with the U.S. Department of Health and Human Services on May 19, even though Myriad Genetics agreed to release the data to the patients.

    Comment?

  4. Myriad Genetics embroiled in breast-cancer data fight - againRead the original story w/Photo

    Friday May 20 | Nature

    Genetic-testing firm Myriad Genetics is facing a legal challenge from people who say the company refused to give them access to their own genomic data, in violation of a US government rule on medical records. Although Myriad has now agreed to release the data to those individuals, the patients are pressing ahead with their complaint to the US government.

    Comment?

  5. Bull Vs. Bear: Myriad Genetics, Inc.Read the original story w/Photo

    Wednesday May 25 | Fox News

    Myriad Genetics, Inc. , a specialty molecular-diagnostic laboratory that develops novel tests to help physicians and patients make better decisions, put up some big gains late last year only to give them up: Recently, the the stock plunged, and is near a 52-week low. Is it a good time to get in now, or could there be more losses ahead? To help answer that question, we asked two of our Motley Fool contributors to put their best case for and against investing in Myriad Genetics' stock right now.

    Comment?

  6. The week in science: 20-26 May 2016Read the original story w/Photo

    Wednesday May 25 | NatureNews

    Pandemic war chest unveiled for developing countries; India launches space shuttle; and US National Football League criticized over health-funding pressure. Myriad problems Diagnostics firm Myriad Genetics, in Salt Lake City, Utah, is facing a legal challenge from people who say that the company refused to give them access to their own genomic data, thereby violating a US government rule on medical records.

    Comment?

  7. Myriad Genetics, Inc. (MYGN) Position Raised by Panagora Asset Management Inc.Read the original story w/Photo

    Tuesday May 24 | Daily Political

    Panagora Asset Management Inc. raised its stake in shares of Myriad Genetics, Inc. by 336.9% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 36,672 shares of the company's stock after buying an additional 28,279 shares during the period.

    Comment?

  8. Myriad Genetics Embroiled in Breast-Cancer Data Fight--AgainRead the original story w/Photo

    Tuesday May 24 | Scientific American

    Genetic-testing firm Myriad Genetics is facing a legal challenge from people who say the company refused to give them access to their own genomic data, in violation of a US government rule on medical records. Although Myriad has now agreed to release the data to those individuals, the patients are pressing ahead with their complaint to the US government.

    Comment?

  9. Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Recommendation of "Hold" by AnalystsRead the original story w/Photo

    Monday May 23 | AmericanBankingNews.com

    Shares of Myriad Genetics, Inc. have earned a consensus recommendation of "Hold" from the seventeen brokerages that are covering the stock. Two research analysts have rated the stock with a sell rating, four have given a hold rating and nine have assigned a buy rating to the company.

    Comment?

  10. Subject Matter Eligibility under 35 U.S.C. 101 - Life SciencesRead the original story w/Photo

    Saturday May 21 | JD Supra

    ... to screening for gene alternations and is modeled on issues raised in Association for Molecular Pathology v. Myriad Genetics, Inc. The remaining examples demonstrate the use of the streamlined analysis, using claims from the patents at issue in ...

    Comment?

  11. Biotech Company and Patients Face Off to Gain Access to Their Genetic TestsRead the original story w/Photo

    Friday May 20 | KFOR-AM Lincoln

    A Utah-based biotech company that had refused to let four patients access their full genetic information has reversed course, a day before the American Civil Liberties Union filed a complaint with the federal government on behalf of patients in general. Myriad Genetics provided the patients late Wednesday with genetic information they requested in February.

    Comment?

  12. In Focus BlogACLU Complaint Against Myriad Genetics Suggests Broader Campaign to Compel Data SharingRead the original story w/Photo

    Friday May 20 | The American Journal of Managed Care

    The sequence of events that led to Thursday's complaint points to a coordinated effort to challenge Myriad Genetics' long-held position that it does not share information on public databases. A regulatory change that went unnoticed in January has triggered a complaint against Myriad Genetics, a leading molecular diagnostics company at odds with some scientists because it declines to share years' worth of results with public databases.

    Comment?

  13. Myriad Genetics (MYGN) - Analysts' Recent Ratings ChangesRead the original story w/Photo

    Friday May 20 | AmericanBankingNews.com

    They now have a $34.00 price target on the stock, down previously from $42.00. 5/4/2016 - Myriad Genetics had its price target lowered by analysts at Avondale Partners from $50.00 to $47.00.

    Comment?

  14. Myriad Genetics??? Statement On HIPAA Complaint From Four PatientsRead the original story

    Thursday May 19 | BioSpace

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced a complaint was filed against the Company with the Department of Health and Human Services on behalf of four individuals seeking their genetic testing results. The Company believes it has complied with these requests and provided these four patients with their designated record set and all requested personal health information.

    Comment?

  15. Myriad hit with complaint over access to genetic informationRead the original story

    Thursday May 19 | Reuters

    The American Civil Liberties Union on Thursday filed a complaint with the federal government accusing genetic testing company Myriad Genetics Inc of refusing to provide four patients with personal genetic information they requested, though the company has now provided it. The complaint was filed with the U.S. Department of Health and Human Services' Office of Civil Rights, according to the ACLU.

    Comment?

  16. Myriad Genetics To Present New Research At The 2016 ASCO Annual MeetingRead the original story

    Wednesday May 18 | BioSpace

    Data Demonstrate Expanded Utility of the myRiskA Hereditary Cancer Test SALT LAKE CITY, Utah, May 18, 2016 - Myriad Genetics, Inc. today announced it will present data from nine clinical studies with three different products at the 2016 American Society of Clinical Oncology annual meeting to be held June 3-7, 2016 in Chicago, Ill. Key podium presentations will highlight the safety and validity of the myRiskA Hereditary Cancer multigene panel test in assessing hereditary cancer risk.

    Comment?

  17. Myriad Genetics Announces Plans To Launch A Web Portal For Patients...Read the original story

    Wednesday May 18 | BioSpace

    Myriad Genetics , Inc. , a leader in molecular diagnostics and personalized medicine, today announced plans to launch a new web portal on ms360.myriad.com that will allow patients to access their personal test results as well as other high-quality tools and ideas to help them make healthcare decisions. "Nothing is more important to us than empowering and improving people's lives," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetic Laboratories.

    Comment?

  18. Better Buy: Myriad Genetics, Inc. vs. Exact SciencesRead the original story w/Photo

    Tuesday May 17 | The Motley Fool

    ... chance to take, and one I wouldn't recommend to the bravest investor. I'd recommend waiting to see how well Myriad Genetics can compete in the cutthroat, low-margin diagnostics business. That said, it is profitable, and growing -- two key features ...

    Comment?

  19. Myriad Genetics, Inc. (MYGN) Stake Lowered by Euclidean Technologies Management LLCRead the original story w/Photo

    Friday May 13 | Daily Political

    Euclidean Technologies Management LLC decreased its position in Myriad Genetics, Inc. by 39.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,917 shares of the company's stock after selling 26,362 shares during the period.

    Comment?

  20. Crescendo Bioscience Launches Web Portal for Patients with Rheumatoid ArthritisRead the original story

    Wednesday May 11 | PressReleasePoint

    SOUTH SAN FRANCISCO, Calif., May 11, 2016 -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. , today announced that it has launched a new web-based portal called myVectra for patients with rheumatoid arthritis . myVectra provides patients with easy access to their Vectra DA test results and test history, which can help them to prepare for visits with their rheumatologist.

    Comment?